Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules SYS-CON Media (press release) Rebif (interferon beta-1a; Merck Serono) forecast2.14.Extavia (interferon beta-1b; Novartis) forecast2.15.Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast2.16.Laquinimod (Teva/Active Biotech) forecast2.17.Daclizumab HYP (Biogen/AbbVie) forecast2.18. |
